Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Rituximab in High-Risk CLL
NCT01625741Phase 2Terminated
- Start
- Jul 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in chronic lymphocytic leukemia (CLL). Started Jul 2012; status: terminated.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01625741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625741.